JNJ vs JPM: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$350.13
+26.9% upside to fair value
Med Conviction
Grade A-
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+26.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
JPM |
| Current Price |
$270.68 |
$350.13 |
| Fair Value Estimate |
$286.05 |
$444.48 |
| Upside to Fair Value |
+5.7%
|
+26.9%
|
| Market Cap |
$652.3B |
$938.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.2x
|
20.0x
|
| Price / Sales |
6.7x
|
3.1x
|
| Price / FCF |
35.3x
|
—
|
| Revenue Growth YoY |
+6.6%
|
+17.9%
|
| Gross Margin |
67.9%
|
62.6%
|
| Operating Margin |
26.8%
|
28.2%
|
| Return on Equity |
25.7%
|
17.8%
|
| Dividend Yield |
1.95% |
1.71% |
| FCF Yield |
2.83%
|
—
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
JPMorgan Chase is a diversified global bank spanning consumer banking, cards, payments, commercial banking, investment banking, markets, treasury services, and asset and wealth management, with an unusually high-quality franchise supported by funding scale, distribution, leading market positions and cross-selling across 86.6 million U.S. consumers and more than 90% of Fortune 500 companies. Busin…
Accumulation Zones
| Metric |
JNJ |
JPM |
| Zone Low |
$214.54 |
$333.36 |
| Zone High |
$243.14 |
$377.81 |
| In Buy Zone? |
No
|
Yes
|